查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771462

美国兽医神经退化性疾病诊断市场：市场规模、份额、趋势分析（按诊断测试、动物类型、产品类型、适应症、最终用途）、细分市场预测（2025-2030 年）

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Tests, By Animal Type, By Product, By Indication, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国兽医神经退化性疾病诊断市场的成长与趋势

根据 Grand View Research, Inc. 的新报告，美国兽医神经退化性疾病诊断市场预计到 2030 年将达到 1.5844 亿美元，2025 年至 2030 年的复合年增长率为 7.3%。

推动市场成长的主要因素包括研究倡议的不断扩展、神经退化性疾病盛行率的上升以及倡导倡议的不断推进。犬类认知功能障碍 (CCD) 和猫科动物认知功能障碍 (FCD) 等疾病正得到越来越广泛的关注，研究表明，近 73% 的老年犬和 50% 的老年猫出现认知能力下降的征兆。宠物饲主和兽医的这种意识不断增强，推动了对早期精准诊断工具的需求。

技术创新正在推动该领域的发展：人工智慧成像技术可以更准确地解释X射线、超音波和MRI，从而可以更早发现神经退化性疾病，而先进的分子诊断方法（包括基于PCR的检测和次世代定序）可以更准确地识别疾病标誌物，反映了精准医疗的更广泛趋势。

研究也取得了显着进展。某些曾被认为有望用于诊断神经退化性疾病的基因标记，根据新的研究已被否定，这凸显了能够跟上科学知识发展步伐的诊断技术的重要性。诸如用于牛脑病变(BSE) 监测的法律规范，证明了政府监管在疾病控制中的关键作用。这些项目凸显了全面监测和可靠诊断对于维护动物和人类健康的重要性。

除了监测之外，生物标记发现、影像技术和神经行为测试的进步也持续改变诊断领域。这些进步支持早期疗育和更完善的疾病管理，推动着该领域持续创新。公众意识提升宣传活动和倡议工作也发挥关键作用，推动研发投入。人们对诊断测试日益增长的兴趣反映了兽医学和人类医学的通用目标：更有效地应对神经退化性疾病。

美国兽医神经退化性疾病诊断市场：概述

  • 从产品来看，预计耗材、试剂和套件细分市场将在2024年占据最大的收益占有率，并在预测期内实现最快的复合年增长率。这种主导地位归因于这些产品对于常规检测至关重要，能够为兽医提供经济高效、便捷且标准化的解决方案。这些产品常用于基因筛检、生物标记检测和免疫测量，而这些是诊断犬隻认知功能障碍等疾病的关键工具。
  • 根据诊断测试，影像学领域将在2024年占据最大的市场占有率，达到45.6%。该领域包括MRI和电脑断层扫描等诊断影像学测试，其主导地位归功于其能够提供详细的高解析度脑部影像，有助于检测细微的结构变化。这些测试有助于区分重迭的临床状况，并且由于是非侵入性的，因此可以安全地重复使用。
  • 根据动物类型，预计伴侣动物将在2024年主导美国兽医神经退化性疾病诊断行业，并在预测期内以最快的复合年增长率增长。该细分市场包括犬、猫和马等动物，其主要驱动力是宠物拥有率的上升以及人们对犬退化性脊髓型颈椎病变、马小脑萎缩和犬认知功能障碍等神经退化性疾病认识的提高。
  • 根据适应症，认知功能障碍细分市场预计将在2024年占据最大的收益占有率，并在预测期内以最快的复合年增长率成长。在美国，这些诊断测试主要用于诊断认知功能障碍综合症（CDS），因为这类疾病在老年伴侣动物中非常普遍，尤其是狗和猫，它们构成了宠物饲养的最大群体。

目录

第一章 分析方法与范围

第二章执行摘要

第三章美国兽医神经退化性疾病诊断市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场
    • 附随市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
    • 市场机会分析
    • 市场问题分析
  • 美国兽医神经退化性疾病诊断市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析
    • 法律规范
    • 定价分析
    • 宠物主人人口统计
    • 以主要国家和物种估计的动物数量（2024 年）

第四章美国兽医神经退化性疾病诊断市场：按动物类型进行的估计和趋势分析

  • 细分仪表板
  • 美国兽医神经退化性疾病诊断市场趋势分析（按动物类型）
  • 美国兽医神经退化性疾病诊断市场规模及趋势分析（依动物类型）（2018-2030）
  • 家畜
    • 羊
    • 牛
    • 其他的
  • 伴侣动物
    • 犬科动物
    • 猫科
    • 马
    • 其他的

第五章美国兽医神经退化性疾病诊断市场：诊断测试的估计和趋势分析

  • 细分仪表板
  • 美国兽医神经退化性疾病诊断市场趋势分析（按诊断测试）
  • 美国兽医神经退化性疾病诊断市场规模及趋势分析（依诊断检验）（2018-2030）
  • 影像学诊断
    • MRI（磁振造影）
    • CT（电脑断层扫描）
    • 其他的
  • 生物标记诊断测试
    • 脑脊髓液（CSF）生物标记物
    • 血液中的生物标记
    • 其他的
  • 其他的

第六章美国兽医神经退化性疾病诊断市场：按产品分類的估计和趋势分析

  • 细分仪表板
  • 美国兽医神经退化性疾病诊断市场趋势分析（按产品）
  • 美国兽医神经退化性疾病诊断市场规模与趋势分析（按产品）（2018-2030）
    • 耗材、试剂和套件
    • 设备/装备

第七章美国兽医神经退化性疾病诊断市场：依适应症的估计与趋势分析

  • 细分仪表板
  • 美国兽医神经退化性疾病诊断市场趋势（按适应症）
  • 美国兽医神经退化性疾病诊断市场规模及趋势分析（2018-2030）
    • 认知障碍
    • 小脑萎缩
    • 脑病变
    • 其他的

第八章美国兽医神经退化性疾病诊断市场：按最终用途的估计和趋势分析

  • 细分仪表板
  • 美国兽医神经退化性疾病诊断市场趋势分析（按最终用途）
  • 美国兽医神经退化性疾病诊断市场规模和趋势分析（按最终用途）（2018-2030 年）
    • 兽医诊所
    • 兽医诊断实验室
    • 其他的

第九章 竞争态势

  • 市场参与企业分类
  • 企业市场分析/热图分析
  • 公司简介
    • Zoetis Services LLC.
    • Vrac .
    • Life Diagnostics.
    • ACUVET BIOTECH
    • Merck &Co., Inc.
    • IDEXX Laboratories, Inc.
    • MI：RNA Diagnostics Ltd.
    • Mercodia AB
    • Antech Diagnostics, Inc.
    • Avacta Animal Health Limited
  • 战略地图
    • 企业合併与收购（M&A）
    • 商业伙伴关係与合作
    • 产品发布
    • 其他的
  • 其他主要企业名单
Product Code: GVR-4-68040-603-5

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Growth & Trends:

The U.S. veterinary neurodegenerative disease diagnostics market size is expected to reach USD 158.44 million by 2030, registering a CAGR of 7.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market growth are growing research initiatives, the rising prevalence of neurodegenerative diseases, and support initiatives. The increasing prevalence of neurodegenerative diseases in animals is fueling rapid growth in the veterinary diagnostics sector in the U.S. Conditions like Canine Cognitive Dysfunction (CCD) and Feline Cognitive Dysfunction (FCD) are becoming more widely recognized, with evidence suggesting that nearly 73% of senior dogs and 50% of senior cats exhibit signs of cognitive decline. This heightened awareness among pet owners and veterinarians has driven demand for early and accurate diagnostic tools.

Technological innovations are propelling this sector forward. AI-enhanced imaging techniques now offer more precise interpretation of X-rays, ultrasounds, and MRIs, enabling the earlier detection of neurodegenerative diseases. Meanwhile, advanced molecular diagnostics-including PCR-based assays and next-generation sequencing-provide more accurate identification of disease markers, reflecting a broader trend toward precision medicine.

Research has also evolved significantly. Specific genetic markers once considered promising for neurodegenerative disease diagnosis have been dismissed based on newer studies, underscoring the importance of adaptable diagnostic technologies that can keep pace with shifting scientific insights. Regulatory frameworks, such as those used in bovine spongiform encephalopathy (BSE) surveillance, demonstrate the crucial role of government oversight in disease control. These programs highlight how comprehensive monitoring and robust diagnostics are vital for maintaining animal and human health.

Beyond surveillance, progress in biomarker discovery, imaging technologies, and neurobehavioral testing continues to transform the diagnostic landscape. These advancements support earlier intervention and better disease management, driving the sector toward continuous innovation. Public awareness campaigns and advocacy efforts have also played a pivotal role, boosting investment in research and development. This surge of interest in diagnostic testing reflects a shared priority-across both veterinary and human medicine-to address neurodegenerative diseases more effectively.

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Report Highlights:

  • Based on product, consumables, reagents, and kits segment held the largest revenue share in 2024, and is expected to grow at the fastest CAGR over the forecast period. This dominance can be attributed to these products being essential for routine testing, offering cost-effective, convenient, and standardized solutions for veterinarians. These products are frequently used in genetic screening, biomarker assays, and immunoassays and are key tools for diagnosing conditions like canine cognitive dysfunction.
  • Based on diagnostic tests, the imaging segment held the largest market share of 45.6% in 2024. This segment consists of imaging diagnostic tests such as MRI and CT scans, whose dominance can be attributed to their ability to provide detailed, high-resolution images of the brain, which aid in detecting subtle structural changes. They help differentiate between overlapping clinical signs and are non-invasive, making them safe for repeated use.
  • Based on animal type, the companion animal segment dominated the U.S. veterinary neurodegenerative disease diagnostics industry in 2024 and is also expected to grow at the fastest CAGR over the forecast period. This segment, which includes animals such as canines, felines, equines, etc., is mainly driven by rising pet ownership and increased awareness of neurodegenerative conditions like degenerative myelopathy in dogs, cerebellar abiotrophy in horses, and canine cognitive dysfunction.
  • Based on indication, the cognitive dysfunction segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. In the U.S., these diagnostic tests are most commonly conducted for cognitive dysfunction syndrome (CDS) primarily because it is highly prevalent among aging companion animals, especially dogs and cats, constituting the largest segment of pet ownership.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Research Initiatives
      • 3.2.1.2. Rising Prevalence of Neurodegenerative Diseases
      • 3.2.1.3. Support Initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of standardized regulations
      • 3.2.2.2. Lack of awareness in developing economies
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Pet Ownership Demographics
    • 3.3.6. Estimated Animal Population by key countries, key species, 2024

Chapter 4. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Animal Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Animal type Movement Analysis
  • 4.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by animal type, 2018 to 2030 (USD Million)
  • 4.4. Livestock
    • 4.4.1. Livestock Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Sheep
      • 4.4.2.1. Sheep Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Cattle
      • 4.4.3.1. Cattle Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Companion
    • 4.5.1. Companion Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Canine
      • 4.5.2.1. Canine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Feline
      • 4.5.3.1. Feline Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Equine
      • 4.5.4.1. Equine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests Movement Analysis
  • 5.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by Diagnostic Tests, 2018 to 2030 (USD Million)
  • 5.4. Imaging
    • 5.4.1. Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. MRI (Magnetic Resonance Imaging)
      • 5.4.2.1. MRI (Magnetic Resonance Imaging) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. CT (Computed Tomography)
      • 5.4.3.1. CT (Computed Tomography) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biomarker Diagnostic Tests
    • 5.5.1. Biomarker Diagnostic Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. CSF (Cerebrospinal Fluid) biomarkers
      • 5.5.2.1. CSF (Cerebrospinal Fluid) biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Blood-based biomarkers
      • 5.5.3.1. Blood-based biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. Others
      • 5.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Product Movement Analysis
  • 6.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
    • 6.3.1. Consumables, Reagents & Kits
      • 6.3.1.1. Consumables, Reagents & Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Equipment & Instruments
      • 6.3.2.1. Equipment & Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Indication Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Indication, Movement Analysis
  • 7.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 7.3.1. Cognitive Dysfunction
      • 7.3.1.1. Cognitive Dysfunction Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Cerebellar Abiotrophy
      • 7.3.2.1. Cerebellar Abiotrophy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Spongiform Encephalopathies
      • 7.3.3.1. Spongiform Encephalopathies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Others
      • 7.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By End Use Movement Analysis
  • 8.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
    • 8.3.1. Veterinary Hospitals and Clinics
      • 8.3.1.1. Veterinary Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Veterinary Diagnostic Laboratories
      • 8.3.2.1. Veterinary Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Others
      • 8.3.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heat Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Zoetis Services LLC.
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Vrac .
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Life Diagnostics.
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. ACUVET BIOTECH
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Merck & Co., Inc.
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. IDEXX Laboratories, Inc.
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. MI:RNA Diagnostics Ltd.
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Mercodia AB
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Antech Diagnostics, Inc.
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Avacta Animal Health Limited
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Product launch
    • 9.4.4. Others
  • 9.5. List of other key players

List of Tables

  • Table 1 List of secondary sources
  • Table 2 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Animal type, 2018 - 2030 (USD Million)
  • Table 3 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Indication, 2018 - 2030 (USD Million)
  • Table 4 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Diagnostic Tests, 2018 - 2030 (USD Million)
  • Table 5 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Company Overview
  • Table 8 Product Benchmarking
  • Table 9 Financial Performance
  • Table 10 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Veterinary Neurodegenerative Disease Diagnostics Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 U.S. Veterinary Neurodegenerative Disease Diagnostics Market snapshot
  • Fig. 11 U.S. Veterinary Neurodegenerative Disease Diagnostics Market driver impact
  • Fig. 12 U.S. Veterinary Neurodegenerative Disease Diagnostics Market restraint impact
  • Fig. 13 U.S. Veterinary Neurodegenerative Disease Diagnostics animal type key takeaways (USD Million)
  • Fig. 14 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: animal Type movement analysis
  • Fig. 15 Companion market, 2018 - 2030 (USD Million)
  • Fig. 16 canine market, 2018 - 2030 (USD Million)
  • Fig. 17 Feline market, 2018 - 2030 (USD Million)
  • Fig. 18 Equine market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Livestock market, 2018 - 2030 (USD Million)
  • Fig. 21 Sheep market, 2018 - 2030 (USD Million)
  • Fig. 22 Cattle market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Veterinary Neurodegenerative Disease Diagnostics Market Product Key Takeaways (USD Million)
  • Fig. 25 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: product movement analysis
  • Fig. 26 Consumables, Reagents & Kits market, 2018 - 2030 (USD Million)
  • Fig. 27 Equipment & Instruments market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Veterinary Neurodegenerative Disease Diagnostics Market Diagnostic Tests key takeaways (USD Million)
  • Fig. 29 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests movement analysis
  • Fig. 30 Imaging market, 2018 - 2030 (USD Million)
  • Fig. 31 MRI (Magnetic Resonance Imaging) market, 2018 - 2030 (USD Million)
  • Fig. 32 CT (Computed Tomography) market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Biomarker Diagnostic Tests market, 2018 - 2030 (USD Million)
  • Fig. 35 CSF (Cerebrospinal Fluid) biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 36 Blood-based biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Veterinary Neurodegenerative Disease Diagnostics Market Indication Key Takeaways (USD Million)
  • Fig. 40 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Indication movement analysis
  • Fig. 41 Cognitive Dysfunction market, 2018 - 2030 (USD Million)
  • Fig. 42 Cerebellar Abiotrophy Flow Assays market, 2018 - 2030 (USD Million)
  • Fig. 43 Spongiform Encephalopathies market, 2018 - 2030 (USD Million)
  • Fig. 44 Others market, 2018 - 2030 (USD Million)
  • Fig. 45 Veterinary Neurodegenerative Disease Diagnostics Market by End Use key takeaways (USD Million)
  • Fig. 46 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: by End Use movement analysis
  • Fig. 47 Veterinary Diagnostic Laboratories market, 2018 - 2030 (USD Million)
  • Fig. 48 Veterinary Hospitals and Clinics market, 2018 - 2030 (USD Million)
  • Fig. 49 Others market, 2018 - 2030 (USD Million)
  • Fig. 50 Market participant categorization